← Eichor
Condition: Peripheral Blood Stem Cell Transplantation Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Peripheral Blood Stem Cell Transplantation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Ce
Phase 1 · 21 location(s) · TScan Therapeutics, Inc. · NCT05473910MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880Methods of T Cell Depletion Trial (MoTD)
Phase 2 · 17 location(s) · University of Birmingham · NCT04888741Haplo-Cord HSCT for AML/MDS
NA · 4 location(s) · Fujian Medical University Union Hospital · NCT07588360Risk Stratification and MRD-driven Maintenance for MM After ASCT
NA · 4 location(s) · Peking University People's Hospital · NCT06697483Compassionate Access of the Miltenyi Device for CD34+ Cell Selection
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT02438904Evaluation of a PREHABilitation Protocol Using Adapted Physical Activity (APA) for Multiple Myeloma Patients Eligible fo
NA · 1 location(s) · Centre Hospitalier Henri Duffaut - Avignon · NCT06789003ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07106710Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
Phase 3 · 4 location(s) · Center for International Blood and Marrow Transplant Researc · NCT00785525Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
Phase 3 · 2 location(s) · Guangzhou Gloria Biosciences Co., Ltd. · NCT06514508A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplan
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06679829A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Mye
Phase N/A · 5 location(s) · Bristol-Myers Squibb · NCT06698887Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Phase 3 · 22 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT04047628The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofet
Phase 1/Phase 2 · 2 location(s) · National Cancer Institute (NCI) · NCT05436418Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT06856226Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
Phase 3 · 69 location(s) · University of Heidelberg Medical Center · NCT06216158Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
NA · 2 location(s) · Dana-Farber Cancer Institute · NCT05706766Mozobil for Autologous Hematopoietic Stem Cell Transplantation
Phase 2 · 1 location(s) · Thomas Jefferson University · NCT07188090High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)
Phase N/A · 1 location(s) · Yigeng Cao,MD,PhD · NCT07205523Long Term Effects On Recipients of Hematopoietic Stem Cell Transplantation
Phase N/A · 1 location(s) · Stanford University · NCT01629017Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia
Phase 1 · 1 location(s) · Beijing 302 Hospital · NCT07297173Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
Phase 3 · 1 location(s) · Augusta University · NCT06588413TBI/Flu/Bu/Mel Combined With Secondary UCBT in Patients With Hematological Malignancies Who Relapsed After Allo-HSCT
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06125483In-utero Hematopoietic Stem Cell Transplantation for the Treatment of Fetuses With Bart's Hydrops Fetalis Syndrome
NA · 1 location(s) · Chinese University of Hong Kong · NCT05797272Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases
Phase 3 · 6 location(s) · Anhui Provincial Hospital · NCT06294691A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patie
Phase 2 · 13 location(s) · Center for International Blood and Marrow Transplant Researc · NCT06859424Helical Tomotherapy in Multiple Myeloma
NA · 1 location(s) · Fuling Zhou · NCT05970198Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma
Phase 1 · 1 location(s) · Hackensack Meridian Health · NCT03909412Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
Phase 2 · 1 location(s) · University of Alabama at Birmingham · NCT04991103CIBMTR Research Database
Phase N/A · 2 location(s) · Center for International Blood and Marrow Transplant Researc · NCT01166009
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.